TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07264634: A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Sponsor: Ascendis Pharma A/S · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$2,988,000

Rescue Site Savings

+$1,958,800

Unlock Full NCT07264634 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07264634 Rescue Dossier →